STK11 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This STK11 Target Evaluation Report is generated from PatSnap Life Sciences MCP data, combining target biology from the Target & Disease MCP Server with clinical landscape evidence from the Clinical Trials MCP Server.
The goal is simple: give R&D teams a fast, structured view of whether STK11 looks attractive enough for deeper target validation, asset scouting, or indication prioritization. The same workflow can be reproduced by AI agents through PatSnap Life Sciences MCP Servers.
7Drug records
Target-linked assets in MCP
5Development drugs
Active or development-stage assets
7Disease links
Indication associations
4Clinical trials
Registered trial matches
Executive Takeaway
STK11 is a strategically important tumor-suppressor and metabolic-sensing node, but the retrieved clinical examples are not classic STK11-directed drug trials. The target is attractive for biomarker-defined strategy and synthetic-lethal discovery.
Biology Signal
Strong biology through LKB1-family kinase signaling, AMPK activation, metabolism, polarity, and tumor-suppressor function.
Clinical Evidence
The Clinical Trials MCP retrieved 4 matches, including nutrition or natural-product intervention studies, so direct target validation remains limited.
R&D Priority
Attractive for biomarker-driven oncology, metabolic vulnerability discovery, and resistance segmentation.
Biology and Disease Rationale
STK11, often discussed as LKB1 biology, sits upstream of AMPK-family signaling and helps coordinate energy stress, metabolism, growth control, and cellular polarity. Loss-of-function biology is especially important because it can create pathway dependencies without making STK11 itself easy to drug directly.
The disease opportunity is most compelling in genetically defined tumors and syndromic contexts where STK11 status changes prognosis, immune contexture, or metabolic vulnerability. MCP disease links support a focused but strategically meaningful landscape.
Validation and Competitive Landscape
The Target & Disease MCP retrieved 7 target-linked drug records, 5 development-stage assets, and 7 disease associations. The Clinical Trials MCP returned 4 registered trial matches for the same target query.
Drug records7
Development assets5
Disease links7
Clinical trial matches4
- Cranberry proanthocyanidins for prevention of urinary tract infection in catheterized neurogenic bladder patients (Phase 3) - Recruiting
- Grape seed proanthocyanidin extract in mild cognitive impairment (Early Phase 1) - Recruiting
- Proanthocyanidins with vitamin C and E in nonalcoholic fatty liver disease (Early Phase 1) - Recruiting
The competitive map should include indirect strategies: AMPK modulators, mTOR-pathway interventions, immune-oncology combinations in STK11-altered tumors, and synthetic-lethal screens. The retrieved clinical studies are useful as signals but should not be interpreted as definitive STK11-directed competition.
Explore PatSnap Life Sciences MCP Servers for AI agents
IP and Partnering Implications
Strong IP positions may come from genotype-defined treatment claims, STK11-loss companion diagnostics, and combinations that address immune-cold or metabolically rewired STK11-altered disease.
Recommended Next Steps
- Use MCP-driven target profiling to confirm disease context, genetic evidence, and pathway dependencies.
- Map clinical trial records against modality, phase, sponsor, and indication to distinguish direct target validation from pathway-adjacent evidence.
- Run IP and asset landscaping before committing to a discovery program or licensing screen.
Prioritize STK11 as a biomarker and vulnerability-discovery axis. A strong program should pair genomic selection with mechanistic assays and clinical trial filters from the MCP workflow.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
